Holen Sie sich die Stockscreener-App
4.34
1.59%
-0.07
Handel nachbörslich:
4.32
-0.02
-0.46%
Schlusskurs vom Vortag:
$4.41
Offen:
$4.4
24-Stunden-Volumen:
1.17M
Relative Volume:
0.56
Marktkapitalisierung:
$857.31M
Einnahmen:
$191.45M
Nettoeinkommen (Verlust:
$160.72M
KGV:
5.2766
EPS:
0.8225
Netto-Cashflow:
$-34.44M
1W Leistung:
-0.91%
1M Leistung:
-9.58%
6M Leistung:
+5.08%
1J Leistung:
+32.32%
1-Tages-Spanne:
$4.27
$4.4495
1-Wochen-Bereich:
$4.26
$4.525
52-Wochen-Spanne:
$3.26
$5.38
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.34 | 871.14M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Corp (ABUS) Cash Flow - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090 - TradingKey
Arbutus Biopharma Corp (ABUS) Balance Sheet - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.440|Chg%:+0.060 - TradingKey
TradingKey - TradingKey
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arbutus Plans $230M Buyback as Patent Fight Expands - MyChesCo
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details - Minichart
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus (ABUS) Plans Share Buyback Program Starting Q3 - GuruFocus
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus awards litigation bonuses to CEO Lindsay Androski; CFO Tuan Nguyen to receive discretionary bonus - TradingView
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks - Yahoo Finance
Arbutus Biopharma stock hits 52-week high at 5.34 USD - Investing.com UK
Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com - Investing.com South Africa
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
ABUS Stock Price, Quote & Chart - ChartMill
ABUSArbutus Biopharma Corp Options - Finviz
Gov't Says It Should Face Vax IP Claims, Not Moderna - Law360
Arbutus Biopharma Corp (ABUS) Institutional Confidence - TradingKey
Arbutus Biopharma Corp (ABUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arbutus Biopharma (ABUS) Edges Higher on Improved Sentiment: Key Levels to WatchConversion Trade - DonanımHaber
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results - Insider Monkey
Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares - Stock Titan
Director at Arbutus Biopharma (ABUS) receives 78,800 fully vested stock options - Stock Titan
Arbutus Biopharma Holds Steady Near Midpoint of Trading RangeSymmetrical Triangle - dars.gov.et
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor - Stock Titan
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):